abc biopply
Swiss preclinical CRO operating the proprietary 3D CoSeedis™ multi-organoid platform, delivering humanized disease models and CRO services for drug efficacy, safety, and toxicity testing to pharmaceutical, biotech, and academic clients globally.
- Company typePrivate
- Founded2018
- HeadquartersSolothurn, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingServices
What abc biopply does
abc biopply AG is a Swiss preclinical contract research organization (CRO) founded in 2018 in Solothurn, Switzerland, operating from facilities in Solothurn, Cham, and a newly opened Organoid Competence Center at Switzerland Innovation Park Basel Area (February 2026). The company commercializes a proprietary 3D cell culture platform called 3D CoSeedis™ Multi-Organoid in chip Technology, which uses agarose chips with conical micro-cavities and a unique permeable matrix to enable spontaneous cell aggregation into humanized multi-organoid micro-tissues. The technology achieves 98.2% uniformity across 200-880 organoids per chip and supports cultures maintained for 75+ days, with formats allowing up to 1,000 replicates. The platform is documented across 20-25 peer-reviewed publications and protected by IP in both the EU and US.
The company serves pharmaceutical and biotech companies (its primary segment) and academic research institutions, providing preclinical CRO services across oncology, neurology, hepatology, and nephrology. Service offerings span standardized packages (e.g., Rapid Drug Efficacy Check, Target Validation Package) delivered in 10-12 weeks, individual assays, and technology licensing under Single Use, Long-Term, and Custom-Tailored models. Revenue streams combine professional services (CRO), licensing/royalties (technology transfer), and hardware sales (3D CoSeedis chips and consumables). Distribution is conducted via direct CRO services from Swiss labs, an international distributor network covering Europe, North America, and Asia, and strategic partnerships (e.g., Preclina for in vivo synchronization, Inoviem Scientific for patient-derived oncology, Pathways Preclinical Partners for US market access).
Commercially, abc biopply operates a sales-led motion built around major industry conferences (BioEurope, Swiss Biotech Day, Festival of Biologics), peer-reviewed publications, webinars, and an industry association presence (Swiss Biotech Association, 3RsC, EUROoCS). The company self-describes as "Europe's first fully integrated organoid CRO" and is positioning as an animal-free alternative for preclinical drug testing, benefiting from the FDA Modernization Act 2.0 regulatory tailwind. The team of approximately 11 listed members is founder-led (Arne Faisst, CEO; Marco Leu, CSO) and privately held, with no disclosed external institutional funding.
abc biopply firmographics
Firmographics- Name
- abc biopply
- Legal name
- abc biopply ag
- Website
- https://biopply.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Swiss preclinical CRO operating the proprietary 3D CoSeedis™ multi-organoid platform, delivering humanized disease models and CRO services for drug efficacy, safety, and toxicity testing to pharmaceutical, biotech, and academic clients globally.
- Ownership category
- akta.pro rank
abc biopply industry classification
Industry- Product category
- Preclinical CRO Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC)
- akta.pro secondary industries
- Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)
Keywords
Where abc biopply is headquartered
LocationHeadquarters
- HQ city
- Solothurn
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
abc biopply business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Preclinical CRO Services: abc biopply provides validated, standardized preclinical CRO services for drug efficacy, safety, toxicity, resistance, and biomarker development. Services are offered as comprehensive service packages (Rapid Drug Efficacy Check, Target Validation Package, Drug Safety Package, Drug Resistance Check, Personalized Efficacy Package, etc.) and individual assay services. Services can be bundled or purchased à la carte.
- Technology and Assay Licensing: Licenses for 3D CoSeedis™ assays and protocols for in-house implementation. Offers Single Use License for one-time access, Long-Term License with training, installation and ongoing support, and Custom-Tailored licenses. Any compound test, assay or disease model can be transferred to client facilities.
- Product Sales (3D CoSeedis™ chips and consumables): Sale of 3D CoSeedis™ chip products and consumables to customers who license the technology. Products include chips in 6-well and 24-well formats with varying numbers of matrices.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Single Use License |
| Subscription | Multi-year contract | Long-Term License |
| Hybrid | Multi-year contract | Custom-Tailored Licensing |
Go-to-market motion1 record
Distribution channels5 records
Marketing channels6 records
abc biopply product offering
Product offeringCore offering
abc biopply provides validated, highly predictive preclinical CRO services for drug efficacy, safety, toxicity, resistance, and biomarker development based on its proprietary 3D CoSeedis™ Multi-Organoid in chip Technology, which uses permeable agarose matrices to generate humanized multi-organoid disease models across oncology, neurology, hepatology, nephrology, and other therapeutic areas. The company sells 3D CoSeedis chips and consumables, licenses assay protocols and disease models (Single Use, Long-Term, and Custom-Tailored licenses), and integrates in vitro with in vivo studies through its partner Preclina for full preclinical pipelines.
Product overview
abc biopply offers the 3D CoSeedis platform, a unified 3D cell culture system comprising proprietary chips and humanized multi-organoid models. The platform enables in-chip organ-to-organ communication studies for preclinical drug testing. Services include CRO offerings (assay development, drug efficacy testing, target validation) across oncology, neurology, hepatology, and nephrology. The company also licenses its technology and intellectual property to partners.
Differentiator
Problem solved
Functional benefit
Products and services
- Preclinical CRO Services Validated, highly predictive preclinical CRO services for drug efficacy, safety, toxicity, resistance, and biomarker development, based on proprietary 3D CoSeedis™ humanized multi-organoid disease models across oncology, neurology, hepatic, renal, and cartilage therapeutic areas. Offered to pharmaceutical and biotech companies as bundled packages or à la carte services, with custom-tailored disease model development and biomarker discovery.
- 3D CoSeedis™ Humanized Multi-Organoid Disease Models Humanized 3D multi-organoid disease models built on the proprietary 3D CoSeedis™ Multi-Organoid in chip Technology, supporting Standard Model for Drug Discovery, Plugin Adaptive Micro-environment, and Plugin Organ-to-Organ Communication. Models are freed from non-human components wherever possible and support oncology, neurology, hepatology, nephrology, and other therapeutic areas.
- 3D CoSeedis™ Chips (6-well and 24-well formats) Agarose chips with conical micro-cavities that allow cells to aggregate spontaneously. One chip grows 200 to 880 organoids for over 75 days, with individual trackability of organoids for analysis. Available in 6-well and 24-well plate formats with varying numbers of matrices; designed for researchers implementing 3D CoSeedis in their own laboratories.
- 3D CoSeedis™ in chip Assays Proprietary assay portfolio including Apoptosis in chip Assay, Co-Culture Assay, Cytotoxicity in chip Assay, Dose Response Assay, Drug Efficacy Assay, Tumor Relapse Assay, Colony Forming in chip Assay, Off-Target Cytotoxicity in chip Assay, and others, delivered as part of the preclinical CRO services.
- Rapid Drug Efficacy Check (Service Package) Standardized service package for rapid assessment of drug efficacy using 3D CoSeedis humanized multi-organoid models, with a 10-week turnaround time to result.
- Target Validation Package Standardized service package for target validation studies using 3D CoSeedis humanized organoid models, with a 12-week turnaround time to result.
- 3D CoSeedis™ Technology Licensing (Single Use, Long-Term, Custom-Tailored Licenses) Licensing of 3D CoSeedis™ assays, protocols, and disease models for in-house implementation at client facilities. Includes a Single Use License for one-time access, a Long-Term License with training, installation, and ongoing support, and Custom-Tailored licensing for any compound test, assay, or disease model transfer; quote-based, multi-year contracts available.
Quantifiable outcome
- 98.2% uniformity and homogeneity of organoids
- +4 more outcomes
Companies that use abc biopply
Customer profileNamed customers4 records
Segments2 records
Ideal customer profiles2 records
abc biopply technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
abc biopply partnerships and signals
Strategic signalPartnerships
18 partnerships are on record, tiered major, supporting, core and regional.
- Pathways Preclinical Partners (Path2P)majorStrategic collaboration announced January 2026 between abc biopply and Pathways Preclinical Partners (Newark, Delaware, USA). Path2P supports broader introduction of abc biopply's 3D CoSeedis technology throughout its professional network of pharmaceutical and biotech companies. Path2P provides regulatory, commercialization, and business development guidance.
- Union Biometrica Inc.supportingCollaboration demonstrating use of 3D CoSeedis technology with Union Biometrica's COPAS VISION system for sorting and dispensing homogeneous organoids in 384-well HTS/HCS formats. Joint white paper showing scalable spheroid production workflow.
- Inoviem ScientificcoreStrategic collaboration between abc biopply and Inoviem Scientific (France) to develop and commercialize a new preclinical oncology service. Integrates Inoviem's fresh patient tumor biopsies with abc biopply's 3D multi-organoid technology. Initially focuses on triple-negative breast cancer (TNBC), with potential for expansion into combination studies and secondary treatment research.
- ZHAW and UZHmajorJoint project with Zurich University of Applied Sciences (ZHAW) and University of Zurich (UZH) to develop a next-generation 3D multi-organoid in vitro platform for immunotherapy testing and personalized cancer therapy. Supported by Swiss national funding agency Innosuisse. Announced August 2025.
- Preclina Inc.coreStrategic collaboration announced January 2025 between abc biopply and Preclina Inc. (Seoul, South Korea). Combines abc biopply's humanized in vitro 3D multi-organoid technology with Preclina's humanized mouse models for end-to-end project planning from early in vitro to in vivo studies. Uses identical source material enabling synchronized, highly predictive preclinical programs.
- ReachBio Research LabsmajorPartnership between abc biopply and Seattle-based ReachBio to jointly market preclinical test models. ReachBio contributes primary cell biology expertise, predictive toxicology, immuno-oncology, cytokine storm risk analysis, ADCC assay services, and hematotoxicity testing. abc biopply contributes multi-organoid systems for systemic drug assessment.
- SEED BiosciencessupportingCollaboration to integrate 3D CoSeedis spheroid production with SEED Biosciences' DISPENCELL automated pipetting robot for individualization of spheroids into HTS-compatible 384-well plates. Enables reliable large-scale 3D culture compound screening.
- nanoscaleLABSregionalUS distribution partner for 3D CoSeedis products in the United States. Located in Fairfax, VA.
- Quadira BiosciencesmajorStrategic partnership to develop therapeutic antibodies without animal testing. Quadira Biosciences (a joint venture of Xlife Sciences AG and anfass Life Technologies AG) gains access to abc biopply's 3D CoSeedis technology for testing and characterizing antibody efficacy in 3D organoid cultures.
- CELLdynamicssupportingCollaboration demonstrating that 3D CoSeedis outperforms conventional 3D cell culture systems in generating highly homogenous and uniform spheroids. Used CELLdynamics' W8 physical cytometry instrument for spheroid characterization.
- Chayon LaboratoriesregionalDistribution partner for 3D CoSeedis products in South Korea. Located in Seoul.
- Funakoshi Co., Ltd.regionalDistribution partner for 3D CoSeedis products in Japan. Located in Tokyo.
- Thistle ScientificregionalDistribution partner for 3D CoSeedis products in UK (England, Wales, Scotland, Northern Ireland). Expert in live cell imaging and cell-based technologies.
- PeloBiotech GmbHregionalDistribution partner for 3D CoSeedis products in Germany and Austria. Located in Planegg/Martinsried, Germany.
- EuromedexregionalDistribution partner for 3D CoSeedis products in France. Located in Souffelweyersheim, France.
- MJS Biolynx Inc.regionalDistribution partner for 3D CoSeedis products in Canada. Located in Brockville, Ontario.
- BioConceptregionalDistribution partner for 3D CoSeedis products in Switzerland.
- AnaPathsupportingPartnership with Swiss-based AnaPath for histological services including paraffin sectioning of 3D cell aggregates grown in 3D CoSeedis matrix. AnaPath provides standardized embedding and sectioning services for immunological analysis of 3D cultures.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
abc biopply competitors and assessment
Company assessmentDirect peers
- InSphero: Swiss-headquartered 3D cell culture and organoid company providing preclinical CRO services for drug efficacy and toxicity testing. Closely comparable in technology focus (3D microtissues), geography (Switzerland/Europe), and customer base (pharma/biotech preclinical).
- MIMETAS: Netherlands-based organ-on-chip company offering preclinical disease models and CRO services. Directly comparable as a NAM-focused preclinical CRO serving pharma R&D with proprietary microfluidic platform technology.
- CN Bio: UK-based organ-on-chip and MPS company providing preclinical CRO services for drug safety and efficacy. Comparable in offering organ-on-chip disease models to pharma with similar regulatory/NAM positioning.
- Hubrecht Organoid Technology (HUB): Dutch organoid technology pioneer providing organoid biobank and disease modeling services to pharma. Comparable in providing standardized human organoid-based preclinical research services and CRO offerings.
Broad incumbents
- Crown Bioscience: Large global preclinical CRO (JSR Life Sciences) offering oncology-focused services including organoid/PDX platforms. Overlaps with abc biopply's oncology preclinical CRO business but at significantly larger scale and broader scope.
- Emulate: US organ-on-chip company commercializing the Emulate Liver-Chip and other human-relevant models for pharma R&D. Comparable NAM positioning with broader portfolio and significantly greater capital base.
- BICO (formerly CELLINK): Global bioconvergence company providing 3D cell culture, bioprinting, and organ-on-chip technologies. Adjacent/overlapping with abc biopply's 3D cell culture platform, though broader portfolio spanning multiple modalities.
Emerging players
- DefiniGEN: UK-based iPSC-derived organoid company providing disease modeling and drug discovery services. Comparable in offering human organoid-based preclinical research but with iPSC rather than multi-organoid chip focus.
- Cellesce: UK-based organoid expansion technology company providing standardized organoid products for drug discovery. Partial overlap as a niche organoid technology provider enabling pharma/biotech preclinical research.
Others
- Molecular Devices: Life science instrumentation company providing 3D cell culture imaging and analysis platforms. Adjacent enabling vendor whose instruments (e.g., high-content imaging) are commonly used alongside organoid workflows like those of abc biopply.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
abc biopply compliance and trust
Trust signalCompliance1 record
abc biopply financial estimates
Financial estimateRevenue estimate
Valuation estimate
abc biopply leadership team
Management profileNumber of profiles
Profiles8 records
abc biopply funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
abc biopply M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about abc biopply
What does abc biopply do?
abc biopply provides validated, highly predictive preclinical CRO services for drug efficacy, safety, toxicity, resistance, and biomarker development based on its proprietary 3D CoSeedis™ Multi-Organoid in chip Technology, which uses permeable agarose matrices to generate humanized multi-organoid disease models across oncology, neurology, hepatology, nephrology, and other therapeutic areas. The company sells 3D CoSeedis chips and consumables, licenses assay protocols and disease models (Single Use, Long-Term, and Custom-Tailored licenses), and integrates in vitro with in vivo studies through its partner Preclina for full preclinical pipelines.
Is abc biopply a public or private company?
abc biopply is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was abc biopply founded?
abc biopply was founded in 2018. It employs 1 to 10 people.
Where is abc biopply based?
abc biopply is headquartered in Solothurn, Switzerland, in the Europe region.
How does abc biopply make money?
Three revenue lines are on record. Preclinical CRO Services are the primary driver. The others are technology and Assay Licensing and product Sales (3D CoSeedis™ chips and consumables).
Who are abc biopply's main competitors?
Direct peers on record are InSphero, MIMETAS, CN Bio and Hubrecht Organoid Technology (HUB). Broad incumbents are Crown Bioscience, Emulate and BICO (formerly CELLINK). Emerging players are DefiniGEN and Cellesce. Molecular Devices is listed as an others.
Does abc biopply have an API?
No public API is recorded for abc biopply.
What industry is abc biopply in?
abc biopply's product category is Preclinical CRO Services. Its primary akta.pro industry code is HLAGAAAC, Toxicology & Safety Assessment CROs (GLP), with a secondary code of HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity). Its NAICS code is 541714 and its SIC code is 8731.